摘要
目的研究肺癌合并慢性阻塞性肺疾病(COPD)患者围术期联合应用盐酸氨溴索和异丙托溴铵的疗效。方法选择2015年至2016年医院收治的肺癌合并COPD患者84例,随机分为对照组和联合用药组,各42例。对照组围术期单纯给予营养支持和抗感染治疗,联合用药组在对照组基础上加用盐酸氨溴索和异丙托溴铵治疗。结果联合用药组疾病缓解率高于对照组(P<0.05);干预后,联合用药组氧分压(PaO_2)和二氧化碳分压(PaCO_2),以及第1秒用力呼气容积(FEV_1)、肺活量(FVC)及通气量均优于对照组(P<0.05)。结论肺癌合并COPD患者围术期联合应用盐酸氨溴索和异丙托溴铵的疗效确切,可有效缓解临床症状,改善患者血气分析指标和呼吸功能,值得推广。
Objective To analyze the effect of ambroxol hydrochloride combined with ipratropium bromide used in the perioperative period of lung cancer complicated with chronic obstructive pulmonary disease（ COPD）. Methods A total of 84 patients with lung cancer complicated with COPD admitted to our hospital from 2015 to 2016 were randomly divided into the control group and the combined medication group,42 cases in each group. The control group was given nutritional support and anti-infection treatment during the perioperative period,on this basis,the combined medication group was given ambroxol hydrochloride combined with ipratropium bromide.Results The rate of disease remission in the combined medication group was higher than that in the control group（ P〈0. 05）. After the intervention,the PaO_2,PaCO_2,FEV_1,FVC and the volume of ventilation in the combined group were better than those in the control group（ P〈0. 05）. Conclusion Ambroxol hydrochloride combined with ipratropium bromide used in the perioperative period of lung cancer complicated with COPD has good effect,it can effectively alleviate the clinical symptoms,improve the blood gas analysis index and respiratory function,which is worthy of clinical promotion.
作者
高克锋
姜姗
刘贵廷
王晴
王晶茹
修艳丽
Gao Kefeng Jiang Shan Liu Guiting Wang Qing Wang Jingru Xiu Yanli(Department of Thoracic Surgery, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang, China 157011 Department of Critical Care Medicine, Mudanjiang Tumour Hospital, Mudanjiang, Heilongjiang, China 157000)
出处
《中国药业》
CAS
2017年第14期71-73,共3页
China Pharmaceuticals
关键词
肺癌
慢性阻塞性肺疾病
围术期
盐酸氨溴索
异丙托溴铵
临床疗效
lung cancer
chronic obstructive pulmonary disease
perioperative period
ambroxol hydrochloride
ipratropium bromide
clinical efficacy
